Fundraising Fox
Menlo Park · Seed–Series C · 42 people tracked
Also known as SAMSARA BIOCAPITAL, LLC
Find your way into Samsara BioCapital
Sign up to see every warm intro you have to Samsara BioCapital
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Samsara BioCapital team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Samsara BioCapital invests in companies working to create transformative therapeutics for patients. The firm brings together scientists, physicians, drug developers, and business leaders with more than 500 years of combined experience to support the next generation of therapeutic breakthroughs. Its approach emphasizes deep scientific and clinical expertise combined with operational and business leadership to build and back drug-development companies across the biopharmaceutical landscape.
Source: firm website, verified Sep 29, 2026.
Team · 42 people
from the firm's website & public directories
Founder mafia
5 people who came through Samsara BioCapital went on to found or lead other companies.
What they invest in
from 84 of 107 portfolio companiesBiotech ×78Healthtech ×49Medical Devices ×33Deep Tech ×22Digital Health ×12AI & Machine Learning ×7Longevity ×3Cleantech ×1
HQs:United States×62Australia×1Canada×1China×1France×1
Who they back
founder profiles across 29 portfolio companiesFounding team size:solo founder×102 founders×73 founders×94+ founders×3
Where their founders studiedfrom 22 founders with education data
University of California, Berkeley ×3University of Science and Technology of China ×3Brown University ×2California State University, Long Beach ×2UC San Diego ×2
What their founders studiedfrom 21 founders with field-of-study data
Life Sciences ×9Chemistry ×5Medicine ×5Engineering ×2
Where their founders worked beforefrom 26 founders with career history
Principia Biopharma ×3Receptos ×3Avalon BioVentures ×2Broad Institute of MIT and Harvard ×2ClarVista Medical ×2Exelixis ×2Rayze Bio ×2
16 founders hold a PhD · 2 hold an MBA (of 24 with degree data) · backed the same founder in 2+ companies: 2 founders
Investments · 107 tracked
founders shown can be your intro pathBy year:2026 · 42025 · 62024 · 82023 · 52022 · 72021 · 82020 · 72019 · 42018 · 22017 · 52015 · 157 dated
aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease.
BiotechHealthtechMedical DevicesSan Diego, US
Paul Schimmel(Founder)John D. Mendlein(Executive Officer, Director)David Weiner(Executive Officer)inFrederic Chereau(Executive Officer)
BoardAmir Nashat(Non-Management Director)inAkkaraju Srinivas(Non-Management Director)
Board seatSrini Akkaraju· per SEC Form D · $45.8M raise · filed Sep 2017
Co-investorsCardinal PartnersEcoR1 CapitalSofinnova VenturesViking GlobalDomain AssociatesDomain Partners+2 more
Mineralys Therapeutics is a clinical-stage pharmaceutical company developing lorundrostat, a treatment targeting dysregulated aldosterone.
BiotechHealthtechRadnor, US
Eric Warren(Chief Commercial Officer)inAlex Gold(Chief Medical Officer)inAdam Levy(Executive Officer)Alexander Asam(Director)
BoardBrian Taylor Slingsby(Founder & former CEO / Board Director)Olivier Litzka(Director)in
Board seatSrinivas Akkaraju· per SEC Form D
Co-investorsAndera PartnersHBM Healthcare InvestmentsHBM PartnersSR One Capital ManagementYsios CapitalAdams Street Partners+3 more
Neurogene develops gene therapy treatments for rare neurological diseases.
BiotechDeep TechDigital HealthLongevityMedical DevicesNew York, US
Rachel McMinn(Founder and Chief Executive Officer)inRachel McMinn, Ph.D.(Founder and Chief Executive Officer)
BoardCory Freedland(Director)inStephen Biggar(Director)
Board seatRobert Baffi· per SEC Form D
Co-investorsEcoR1 CapitalCasdin CapitalREDMILERTW Investments L.P.William Blair
Nkarta is a biotech company developing allogeneic CAR NK cell therapies for autoimmune diseases, aiming to offer safer and more accessible alternatives to autologous CAR-T treatments.
BiotechHealthtechSouth San Francisco, US
Paul Hastings(Executive Officer, Director)inPaul H.inMatthew Plunkett(Executive Officer)in
BoardJill Carroll(Director)inTiba Aynechi(Director)in
Board seatMichael Dybbs· per SEC Form D
Co-investorsNew Enterprise Associates (NEA)RA CapitalSR One Capital ManagementAmgen VenturesLogosNorwest Venture Partners+1 more
Sutro is a biotech company developing a cell-free protein synthesis platform for the design and manufacturing of complex biologics, particularly cancer therapies and antibody-drug conjugates.
BiotechDeep TechHealthtechMedical DevicesSouth San Francisco, US
William J. Newell(Executive Officer, Director)Jane Chung(Chief Executive Officer)inHans-Peter Gerber(Chief Scientific Officer)inDavid Pauling(Chief Administrative Officer and General Counsel)inJonathan Fawcett(VP, Head of Clinical Development)inDevendra Luhar(SVP, Technical Operations)in
Board seatMichael Bryan Dybbs· per SEC Form D
Co-investorsOwl CapitalRidgeback CapitalSolasta VenturesSV Health InvestorsVida Ventures
vTv Therapeutics is a biopharmaceutical company developing oral, small molecule drugs for diabetes and other chronic diseases.
BiotechDigital HealthMedical DevicesHigh Point, US
Rudy Howard(Executive Officer)inStephen Holcombe(Executive Officer)inLarry Altstiel(Executive Officer)Jeffrey Kindler(Executive Officer, Director)Paul Sekhri(Chairman, President, and Chief Executive Officer)inMichael Tung(Executive Vice President and Chief Financial Officer)in
Board seatSrinivas Akkaraju· per SEC Form D
Co-investorsJDRF T1D Fund
Agios is a biopharmaceutical company developing therapies for rare diseases, with a primary focus on hemolytic anemias including pyruvate kinase deficiency, thalassemia, and sickle cell disease.
BiotechHealthtechMedical Devices
Lewis C. Cantley, Ph.D.(Founder)Tak Mak, Ph.D.(Founder)Craig B. Thompson, M.D.(Founder)Brian Goff(Chief Executive Officer)in
Co-investorsARCH Venture PartnersPortage VenturesThird Rock VenturesFlagship Ventures
Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.
AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US
Martin Babler(President, Chief Executive Officer and Chairman of the Board)inMark Bradley(Chief Development Officer)inKolbot By(SVP, Head of Technical Operations)inJack Danilkowicz(Chief Commercial Officer)inJörn Drappa(Chief Medical Officer)inDavid M Goldstein(Chief Scientific Officer)in
Co-investorsForesite CapitalHBM Healthcare InvestmentsHBM PartnersNextech InvestOrbiMedSR One Capital Management+3 more
Bolt Biotherapeutics is a clinical-stage biotech company developing novel immunotherapies that leverage innate immune system mechanisms to treat cancer.
BiotechHealthtechMedical DevicesSan Francisco, US
Dr. Edgar G. Engleman(Founder)
Co-investorsPfizer Venture InvestmentsPivotal Life SciencesRA CapitalSofinnova VenturesVivo CapitalNan Fung Life Sciences+3 more
Contineum is a biopharmaceutical company developing small molecule drug candidates to treat inflammatory and fibrotic diseases by modulating critical disease pathways.
BiotechHealthtech
Carmine Stengone(President and Chief Executive Officer)inPeter T. Slover(Chief Financial Officer)inDaniel S. Lorrain(Chief Scientific Officer)inTimothy R. Watkins(Chief Medical Officer and Head of Development)in
Co-investorsHadean VenturesRed Tree VentureCasdin CapitalFranklin TempletonJJDCSectoral Asset Management+1 more
Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib, an investigational drug candidate for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
BiotechDigital HealthMedical DevicesSan Diego, US
Faheem Hasnain(Executive Officer, Director)inChristian Waage(Executive Officer)inSheila Gujrathi, MD(Founder)inBryan Giraudo(Executive Officer)Laura Carter, Ph.D.(Executive Officer)Robert Smith(Executive Officer)
Co-investorsARCH Venture PartnersBay City CapitalEcoR1 CapitalFoothill VenturesNew Enterprise Associates (NEA)Pivotal Life Sciences+3 more
Kalaris Therapeutics is a clinical-stage biopharmaceutical company developing treatments for prevalent retinal diseases such as wet AMD, diabetic eye disease, and retinal vein occlusion.
BiotechHealthtechBerkeley Heights, US
Srinivas Akkaraju(Director & Co-founder)Mike Dybbs(Director & Co-founder)inNapoleone Ferrara(Director & Co-Founder)Andrew Oxtoby(CEO & Director)inMatthew Feinsod(CMO)Liisa Bayko(CFO)
Co-investorsInvusRTW Investments L.P.
Late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision.
BiotechSouth San Francisco, US
Josh Lehrer(Executive Officer, Director)Katherine Stultz(Executive Officer)inPhilip Gutry(Executive Officer)Evert Schimmelpennink(Chief Executive Officer, President, Secretary, and Director)Daniel Chevallard(Chief Financial Officer)Shawn Olsson(Chief Commercial Officer)in
Co-investorsVersant Ventures
Palvella Therapeutics develops QTORIN™, a targeted topical formulation of rapamycin designed to treat rare skin diseases including microcystic lymphatic malformations and cutaneous venous malformations by delivering the active ingredient to the dermal layers with minimal systemic absorption.
BiotechDigital HealthHealthtechMedical DevicesWayne, US
Wesley H. Kaupinen(President, Chief Executive Officer and Director)Matthew E. Korenberg(Chief Financial Officer, Treasurer and Secretary)inKathleen Goin(Chief Operating Officer)inJeffrey Martini(Chief Scientific Officer)inAshley Kline(Chief Commercial Officer)in
Co-investorsBioAdvanceFrazier Life SciencesAgent Capital
Prime Medicine develops one-time genetic therapies using Prime Editing, a gene editing technology developed in David R.
BiotechDeep TechHealthtechMedical Devices
Andrew Anzalone(Founder)inDavid Liu(Co-founder)inAllan Reine(Chief Executive Officer)inMohammed Asmal(Chief Medical Officer)inAnn Lee(Chief Technical Officer)inSvetlana Makhni(Chief Financial Officer)in
Co-investorsARCH Venture PartnersGV (Google Ventures)Newpath PartnersF-Prime CapitalOUP (Osage University Partners)Arrive+1 more
Clinical-stage biopharmaceutical company focused on discovery and development of innovative medicines for serious diseases by targeting the Transforming Growth Factor Beta pathway.
BiotechCambridge, US
Nagesh Mahanthappa(Executive Officer, Director)Timothy Springer(Director)Yung H. Chyung(Executive Officer)Elan Z. Ezickson(Executive Officer)Akshay Vaishnaw(President of Research & Development and Director)R. Keith Woods(Chief Operating Officer)in
Co-investorsARCH Venture PartnersEcoR1 CapitalPolaris Partners
SpyGlass Pharma develops a sustained drug delivery platform for treating chronic ophthalmic diseases such as glaucoma, integrating drugs, procedures, and devices for long-term disease control and vision preservation.
BiotechHealthtechMedical DevicesAliso Viejo, US
Glenn Sussman(Co-founder)inMalik Y. Kahook(Co-founder)inPatrick Mooney(CEO)
BoardJake Merrill(Director)Geoff Pardo(Director)Bilal Khan(Director)
Co-investorsNew Enterprise Associates (NEA)RA CapitalSands Capital VenturesVensana Capital
Upstream Bio is a biotechnology company that sponsors clinical trials to develop products under investigation.
BiotechHealthtechWaltham, US
Rand Sutherland(Chief Executive Officer)inAllison Ambrose(General Counsel)inAaron Deykin(Chief Medical Officer & Head of R&D)inMike Gray(Chief Financial Officer and Chief Operating Officer)Adam Houghton(Chief Business Officer)inStacy Price(Chief Technology Officer)in
Co-investorsOrbiMedAccess IndustriesAccess BiotechnologyBain Capital Life SciencesDecheng CapitalHBM Healthcare Investments+5 more
Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.
BiotechHealthtechNewton, US
Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Founder)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)
Board seatMichael Dybbs· per SEC Form D
Co-investorsBain Capital Life SciencesNew Enterprise Associates (NEA)RA CapitalSanofi VenturesMass General Brigham VenturesREDMILE+9 more
Enlaza Therapeutics develops covalent protein therapeutics using its War-Lock technology, which incorporates proprietary unnatural amino acids into protein drugs so they form irreversible covalent bonds with disease-related targets.
BiotechDeep TechSan Diego, US
Sergio Duron(Co-Founder & Chief Executive Officer)inSanford Madigan(Co-Founder, President & Chief Business Officer)inAnaleah Heidt(Chief Scientific Officer)in
BoardJay Lichter(Director)inTighe Reardon(Executive Officer)
Board seatMarcos Milla· per SEC Form D
Co-investorsFrazier Life SciencesLightspeed Venture PartnersAvalon BioVenturesPappas CapitalPfizer Venture InvestmentsJ.P. Morgan Asset Management+1 more
OrsoBio develops therapies to restore energy homeostasis in patients with severe metabolic disorders, drawing on biological research including human liver organoids and insights from metabolic pathways.
BiotechDeep TechMedical DevicesMenlo Park, US
Mani Subramanian(Executive Officer, Director)inGangadhara Ganapati(Executive Officer, Director)Dr. SubramanianDr. Myers
BoardMatthew Young(Director)in
Board seatSrinivas Akkaraju· per SEC Form D
Co-investorsAscenta CapitalLongitude CapitalF-Prime Capital
Alpheus is a clinical-stage biotechnology company developing Porphyrin Metabolite Activation (PoMA™), a drug-led oncology approach designed to treat glioblastoma using proprietary low-intensity ultrasound to activate tumor-localized porphyrin metabolites.
BiotechHealthtechMedical DevicesChanhassen, US
Jeremy Ling(Executive Officer)inSteve Weiner(Executive Officer)Vijay Agarwal(Founder, President and CEO)inWilliam Davis(Executive Officer, Director)
BoardKlaus Veitinger(Director)inImran Eba(Executive Officer)in
Co-investorsOrbiMedHealthQuest CapitalSV Health InvestorsAction Potential Venture Capital Ltd.BrightEdge
Dewpoint Therapeutics develops condensate-modulating drugs by using an integrated platform that maps, measures, and modulates biomolecular condensates to identify druggable targets and disease mechanisms.
AI & Machine LearningBiotechDeep TechBoston, US
Richard Young, Ph.D.(Director)inAnthony Hyman, Ph.D.(Director)Tony Hyman(Scientific Co-founder)Rick Young(Scientific Co-founder)Elisabeth Leiderman(Executive Officer)inIsaac Klein, M.D., Ph.D.(Executive Officer)
Co-investorsARCH Venture PartnersEcoR1 CapitalGeneral Catalyst6 Dimensions CapitalInnovation EndeavorsLeaps by Bayer+6 more
.png)
Enara Bio discovers and validates Dark Antigens from non-coding genomic regions to identify novel cancer targets, and develops first-in-class bispecific T-cell engagers against these targets through its EnTiCE platform.
BiotechDeep TechMedical Devices
George Kassiotis(Co-founder)Drew Pardoll(Co-founder)Houman Ashrafian(Co-founder)in
Co-investorsRA CapitalSV Health InvestorsPfizer VenturesDementia Discovery FundM VenturesPfizer Venture Investments
Link Cell Therapies is a biotechnology company developing logic-gate LINK CAR-T cell therapies aimed at treating solid and liquid tumors.
BiotechHealthtech
Robbie MajznerCrystal MackallJerry Cacia(Chief Operating Officer)inMark Wallet(Chief Scientific Officer)in
Co-investorsWing
Lumen develops orally delivered antibody drugs using engineered spirulina, a patented biologic platform that reduces manufacturing costs and timelines compared to conventional biologics.
BiotechDeep TechHealthtechMedical DevicesSeattle, US
Brian Finrow(Founder)in
Co-investorsWestRiver Group
Normunity develops biologic anti-cancer therapies that act at the interface of the immune system and tumors, targeting mechanisms tumors use to evade immune surveillance.
BiotechHealthtech
Rachel Humphrey(Founding Chief Executive Officer)inLieping Chen(Scientific Founder)Mitchell Keegan(Chief Development Officer)inWilliam LaRochelle(Chief Scientific Officer)inStacy M. Plum(Chief Technology Officer)
Co-investorsSanofi VenturesTaiho Ventures, LLCPfizer VenturesCanaan PartnersConnecticut InnovationsOUP (Osage University Partners)+6 more
Ottimo is a biotech company developing oncology and immuno-oncology therapeutics, including antibody-based cancer treatments.
BiotechHealthtech
Jonny Finlay(Founder and Chief Scientific Advisor)David Epstein(Chair & Chief Executive Officer)inMehdi Shahidi(Head of Development & Chief Medical Officer)Ling Zeng(General Counsel and EVP of Execution)inSpencer Fisk(Chief Technical and Quality Officer)
Co-investorsOrbiMedMedicxiAvoro Capital AdvisorsJMI Equity
PsiThera is a biotechnology company using computational and physics-based methods—including quantum mechanics, molecular dynamics, machine learning, and simulation—for mechanism-driven drug design and discovery.
AI & Machine LearningBiotechDeep Tech
Co-investorsLightstone Ventures
Synthekine is a clinical-stage biotechnology company using protein engineering platforms to develop cytokine-based immunotherapies designed to preserve therapeutic efficacy while avoiding toxicities linked to cytokine pleiotropy.
BiotechHealthtech
K. Christopher Garcia(Founder)Susan Molineaux(CEO)inMartin Oft(Chief Scientific Officer)inNaiyer Rizvi(Chief Medical Officer)inGregory(Chief Technical Officer)Geoff(Chief Business Officer)
Co-investorsThe Column GroupBain Capital Life SciencesCanaan PartnersRA CapitalTCG CrossoverDeerfield Management Company+2 more
Tentarix Biotherapeutics develops multifunctional biologics to modernize healthcare standards through precision medicine.
BiotechDeep TechHealthtechMedical Devices
BoardSrini Akkaraju(Director, Founder)inPaul Kang(Director, Founder)
Co-investorsVersant VenturesGilead Sciences
A2 Bio develops precision CAR T-cell therapies using its Tmod cell engineering platform, supporting both autologous and allogeneic applications.
BiotechDeep TechDigital HealthHealthtechMedical DevicesAgoura Hills, US
C. Alexander Kamb(Director)inJim Robinson(CEO)inScott Foraker(Executive Officer, Director)Madhavan Balachandran(Director)Michael Gallo(Director)
Board seatSrini Akkaraju· per SEC Form D
Co-investorsMana VenturesNextech InvestThe Column GroupVida Ventures
DELFI Diagnostics develops FirstLook Lung, a blood-based laboratory test for lung cancer screening that identifies genome-wide alterations in individuals eligible for screening.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesBaltimore, US
Victor Velculescu(Founder)inPeter Bach(Executive Officer)Jennifer Buechel(Executive Officer)Douglas Schenkel(Executive Officer)Nicholas Dracopoli(Executive Officer)inSusan Tousi(Chief Executive Officer)in
Board seatMichael Dybbs· per SEC Form D
Co-investorsAV8 VenturesForesite CapitalIllumina VenturesInitiate Venture PartnersMenlo VenturesMerck Global Health Innovation Fund+7 more
Lumen Bioscience develops orally and intranasally delivered biologic drugs and protein-based nutrition products using genetically engineered spirulina algae to express therapeutic proteins such as antibodies, enzymes, and cytokines.
BiotechDeep TechHealthtechSeattle, US
Erik Anderson(Director)Mark Litton(Director)Robert Carlson(Director)Craig Behnke(Executive Officer)Ed Schlect(Director)John Morrow(Executive Officer)
Board seatMarcos Milla· per SEC Form D · $23M raise · filed Apr 2025
BiotechSouth San Francisco, US
MARTIN BABLER(Executive Officer, Director)in
BoardPETER THOMPSON(Director)inSIMEON GEORGE(Director)LEWIS J. SHUSTER(Director)
Board seatSrinivas AkkarajuMichael Dybbs· per SEC Form D · $50M raise · filed Sep 2018
Co-investorsAccess BiotechnologyMission BiocapitalSofinnova VenturesSR One Capital ManagementMission Bay CapitalNew Leaf Venture Partners+1 more
Syros Pharmaceuticals is a Massachusetts gene-control biotech developing small molecules that regulate disease gene expression.
BiotechCambridge, US
Nancy Simonian(CEO)Peter Wirth(Director)Mark Alles(Director)Philip Sharp(Director)Richard A. Young(Director)Sue Gail Eckhardt(Director)
Board seatSrinivas Akkaraju· per SEC Form D
Co-investorsAisling CapitalARCH Venture PartnersQuan CapitalAlexandriaAlly Bridge GroupBain Capital+11 more
Abivax develops obefazimod, an orally administered small molecule drug candidate with a novel mechanism of action targeting microRNA biology to treat chronic inflammatory diseases including ulcerative colitis and Crohn's disease.
BiotechHealthtechMedical DevicesParis, FR
Marc de Garidel(CEO)in
Co-investorsAndera PartnersClaret Capital PartnersMedicxiSofinnova PartnersTruffle CapitalMorgan Stanley
AI & Machine LearningBiotechDigital HealthHealthtech
Co-investorsDecheng CapitalvenBio PartnersAccess IndustriesKleiner PerkinsWestlake Village BioPartners
Adverum is a clinical-stage gene therapy company developing Ixo-vec, an investigational single-administration intravitreal treatment for wet age-related macular degeneration and other ocular diseases, based on a proprietary adeno-associated virus (AAV) vector platform.
BiotechDeep TechHealthtechRedwood City, US
Thomas W. Chalberg(Executive Officer, Director)Steven D. Schwartz(Director)Mark S. Blumenkranz(Director)Linda Rubinstein(Executive Officer)Setareh Seyedkazemi(Executive Officer)Kishor Peter Soparkar(Executive Officer)
Co-investorsAvoro Capital AdvisorsFrazier Life Sciences5AM VenturesVenrock Healthcare Capital PartnersVivo Capital
Alamar Biosciences develops NULISA, an ultra-high-sensitivity, high-specificity technology for analyzing hundreds of protein biomarkers from small biofluid samples, building on the team's prior spatial genomics work (RNAscope).
BiotechDeep TechHealthtechFremont, US
Yuling Luo(Co-founder, CEO and Chair)inSteve Chen(Co-founder, COO and Director)inYiyuan Yin(Co-founder, VP of Technology)inTod White(President)inJustin McAnear(CFO)inXiao-Jun Ma(CTO)
Co-investorsIllumina VenturesQiming Venture Partners
Portfolio company that completed a successful 2018 biotech IPO, resulting in a 9x return for RiverVest.
BiotechSan Carlos, US
Nenad Tomasevic(Executive Officer)Christopher Bebbington(Executive Officer, Director)Alejandro Dorenbaum(Executive Officer)
BoardFarah Champsi(Director)inJohn McKearn(Director)inPeter Moldt(Director)
Co-investorsAlta PartnersLifeSci Venture PartnersNew Enterprise Associates (NEA)RiverVest Venture PartnersRoche Venture Fund
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(Founder)Kuo-Shyan Lin(Founder)David Perrin(Founder)
Co-investorsAndreessen HorowitzAscenta CapitalDelos CapitalFrazier Life SciencesGeneral CatalystLightspeed Venture Partners+9 more
Alpha-9 is a clinical-stage radiopharmaceutical company developing a portfolio of targeted molecules to treat cancer cells with precision.
BiotechLongevityMedical DevicesBoston, US
Co-investorsFrazier Life SciencesWUTIF CapitalAscenta CapitalBiotechnology Value FundLightspeed Venture PartnersLongitude Capital+1 more
Arcellx develops CAR T-cell therapies that are individually designed for each patient, using the immune system to target and attack cancer.
BiotechHealthtechGaithersburg, US
Han Lee(Executive Officer)Rami Elghandour(Executive Officer, Director)in
BoardJill Carroll(Director)inAli Behbahani(Director)inDerek Yoon(Director)inTiba Aynechi(Director)in
Co-investorsLG Technology VenturesNew Enterprise Associates (NEA)Quan CapitalSixty Degree CapitalSolasta VenturesSR One Capital Management+4 more
Attralus develops pan-amyloid removal (PAR) therapeutics — biologics and imaging agents designed to bind and remove toxic amyloid — to treat patients with systemic amyloidosis across all disease types and stages.
BiotechHealthtechSouth San Francisco, US
Jonathan Wall(Executive Officer)inSpencer Guthrie(Executive Officer)Mark Timney(Executive Officer, Director)inBenson Fong(Executive Officer)Rahul Kakkar(Director)inGreg Bell(Executive Officer)
Co-investorsAlpha Wave GlobalBioBritLifeSci Venture PartnersvenBio PartnersJanus Henderson InvestorsREDMILE+2 more
Autobahn Therapeutics develops orally administered small molecule prodrugs using a brain-targeting chemistry platform to create regenerative medicines for central nervous system (CNS) disorders.
BiotechDeep TechMedical DevicesSan Diego, US
Kevin Finney(Chairman, President and CEO)inJohn Borkholder(Executive Officer)in
BoardKristina Burow(Director)inThomas Cahill(Director)Timothy Anderson(Director)Philip J DeSouza(Director)
Co-investorsARCH Venture PartnersCanaan PartnersMonograph Capital PartnersPfizer Venture InvestmentsInsight PartnersNewpath Partners
CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.
BiotechHealthtechSan Diego, US
Ken Song(Chairman, President and CEO)inKenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)inBernie Huyghe, Ph.D.(Executive Officer)
BoardJeffrey Tong, Ph.D.(Director)
Co-investorsForesite CapitalLifeSci Venture PartnersOrbiMedTCG CrossoverThird Rock VenturesvenBio Partners+2 more
Launched by Samsara in partnership with CAR T pioneers, advancing a clinically validated CD22 CAR T for lymphoma.
BiotechSan Mateo, US
Gina Chapman(Executive Officer, Director)inAnup Radhakrishnan(Executive Officer)inCassandra Gianna Luca(Director)Jeffrey Walsh(Director)Krishnan Viswanadhan(Director)
BoardAbraham Bassan(Director)
Co-investorsNextech InvestRed Tree VentureWellington ManagementAlly Bridge GroupJanus Henderson InvestorsPerceptive Xontogeny Venture+1 more
Claris Bio develops biologic therapies for sight-threatening eye diseases, with a current focus on bringing CSB-001, a novel treatment for patients with limbal stem cell deficiency, through clinical development and to market.
BiotechHealthtechMedical DevicesJersey City, US
Clarke Atwell(Co-Founder and Chief Operating Officer)inHenry Rath(Executive Officer)Susan Orr(Executive Officer)inStephen Brady(Executive Officer, Director)Michael Dybbs(Director)Matt Hobson(Director)
Co-investorsCatalio Capital Management, LPRA CapitalSofinnova VenturesCatalio Capital ManagementNovo Holdings
Coultreon is a drug discovery and development company that advances small and large molecule therapeutic programmes across various disease areas, combining disease biology expertise with technology platforms.
AI & Machine LearningBiotech
Pierre Raboisson(Chief Executive Officer Chief Scientific Officer Co-founder)inMarie De Vulder(Chief Legal Officer Co-founder)inGuy Peeters(Chief Financial Officer Co-founder)inJohn-Paul Gallivan(Head of Development Co-founder)inFabrice Kolb(Head of Immunology Co-founder)inPieter Peeters(Operating & Technology Officer Co-founder)in
Co-investorsFinchley Healthcare VenturesLongwood FundLuma GroupSofinnova VenturesBAM ElevateForbion+2 more
Dewpoint Innovations develops functional nanostructured polymeric surfaces for atmospheric water capture, technology originating from PhD research at the University of Sydney.
CleantechClimate TechDeep TechNew Materials
Chiara Neto(Founder & Advisor (Chief Scientific Officer))inMing Chiu(Founder & CTO)in
Co-investorsImpact Ventures Management Pty LtdPacific Channel3E Bioventures CapitalARCH Venture PartnersEcoR1 CapitalGeneral Catalyst+3 more
Biotechnology company using multiplex gene editing to develop genetically engineered porcine organs for human transplantation.
BiotechBrookline, US
Luhan Yang(President, Secretary and Treasurer)Geoff MacKay(Chief Executive Officer)
BoardGeorge M. Church(Director)
Co-investorsAlta PartnersARCH Venture PartnersCatalio Capital Management, LPHBM Healthcare InvestmentsHBM PartnersKhosla Ventures+12 more
ElevateBio is a contract development and manufacturing organization (CDMO) for advanced therapies, offering discovery, process development, analytics, manufacturing, and regulatory support for cell therapies, viral vectors, mRNA therapeutics, and gene editing.
BiotechDeep TechHealthtechWaltham, US
David Hallal(CEO)inMike Paglia(Chief Technology Officer)Ger Brophy(CEO)in
Co-investorsEcoR1 CapitalMPM BioImpactSoftBank Vision Fund
Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.
BiotechMedical DevicesSan Mateo, US
Ann Lee-Karlon(Executive Officer, Director)inMitchell Mutz(Executive Officer, Director)James Wells(Director)
BoardSamuel Bjork(Director)inAlexandra Cantley(Director)inSeiji Miyahara(Director)in
Co-investorsAvego BioScience CapitalGV (Google Ventures)Mission BiocapitalNovartis Venture FundRoche Venture FundTaiho Ventures, LLC+4 more
Exo Therapeutics is a small molecule drug discovery company developing therapeutics through its ExoSight platform, which targets exosites—unique binding pockets on enzymes—to address previously undruggable diseases in oncology, inflammation, and other therapeutic areas.
BiotechDeep TechMedical Devices
David Liu, PhD(Founder)Alan Saghatelian, PhD(Co-Founder)David LiuinAlan Saghetelian
Co-investorsNewpath PartnersCRV (Charles River Ventures)Nextech InvestRaptor GroupBiotechnology Value FundCasdin Capital+1 more
EyeBio (Eyebiotech Limited), a subsidiary of Merck, develops therapies for retinal diseases such as diabetic macular edema and neovascular age-related macular degeneration, targeting vascular leakage through pathways like Wnt signaling.
BiotechHealthtechHolborn, London
David R. Guyer(Founder, CEO & President)Anthony P. Adamis(Chief Scientific Officer, Co-founder, Director & Chair of Advisory Board)James Allister John Costine(Director)Michael Jay Ross(Executive Officer)Catherine Elizabeth Bingham(Director)
Co-investorsJeito CapitalOmega FundsSV Health Investors
Fluent Bio develops software for analyzing single-cell RNA sequencing data, producing count matrices and diagnostic outputs for researchers using Illumina sequencing libraries.
BiotechDeveloper Tools
Co-investorsCivilization Ventures Management, LlcCota CapitalIllumina Ventures
Genalyte develops Merlin, a real-time diagnostic system that performs laboratory testing directly in clinical settings and integrates results with electronic health records.
Digital HealthHardwareHealthtechMedical DevicesSan Diego, US
Co-investorsBioBritBoutique Venture PartnersClaremont Creek VenturesCLI VenturesFusionX VenturesHBM Healthcare Investments+7 more
XOMA Royalty is a biotech royalty aggregator that acquires the economic rights to future milestone and royalty payments tied to partnered pre-commercial clinical candidates, providing sellers with non-dilutive, non-recourse funding.
BiotechFintech
Co-investorsCatalys PacificFrazier Life SciencesLightspeed Venture PartnersRA CapitalFrazier Healthcare Partners
Intercept Pharmaceuticals develops and commercializes treatments for rare and serious liver and other diseases, with a focus on conditions such as primary biliary cholangitis.
BiotechHealthtechMedical Devices
Co-investorsAisling CapitalBioBritRidgeback Capital
Inventiva is a clinical-stage biopharmaceutical company developing drug candidates, with a focus on liver and other diseases.
BiotechMedical Devices
Co-investorsEuropean Investment BankAndera PartnersClaret Capital PartnersNew Enterprise Associates (NEA)Sofinnova PartnersBiotechnology Value Fund+1 more
IOBiotech appears to be a biotech company focused on oncology, with a founder who has extensive experience in cancer drug development and clinical advancement from roles at Roche, Eli Lilly, and leading academic cancer centers.
BiotechMedical Devices
Dr. Dhingra
Co-investorsAvoro Capital AdvisorsEIR VenturesKurma PartnersPivotal Life SciencesRA CapitalSunstone Capital+3 more
IonPath develops MIBIscope, a spatial proteomics platform that uses multiplexed ion beam imaging to simultaneously measure dozens of protein targets in preserved tissue samples for translational research and discovery.
BiotechDeep TechMedical Devices
Co-investorsHemisphere Ventures LLCNorwich VenturesVertical Venture Partners
Janux Therapeutics is a clinical-stage biotech company developing precision-engineered immunotherapies for the treatment of cancer and autoimmune diseases.
BiotechDeep TechHealthtechMedical DevicesLa Jolla, US
David Campbell, Ph.D.(Executive Officer, Director)inTighe Reardon(Executive Officer)
BoardJay Lichter, Ph.D.(Director)Jake Simson, Ph.D.(Director)Peter Thompson, M.D.(Director)inStefan Heller(Director)
Co-investorsAvalon BioVenturesOrbiMed
HealthtechSkokie, US
Sara Cotter(Executive Officer, Director, Promoter)Michael Dybbs(Director)Sara Brownstein(Director)Terrence Kearney(Director)Daniel Welch(Director)Steven Ryder(Director)
Neurogastrx is a biopharmaceutical company developing therapies for patients with gastrointestinal disorders.
BiotechHealthtechWoburn, US
Cyril De Colle(Founder)inJAMES DETORE(Executive Officer)JAMES O'MARA(Executive Officer, Director)inPAUL ROGERS(Executive Officer)in
BoardDAVID ALLISON(Director)inKLAUS VEITINGER(Director)in
Co-investors5AM VenturesOrbiMedvenBio PartnersVivo CapitalRTW Investments L.P.venBio Global Strategic+1 more
NiKang Therapeutics is a clinical-stage biotechnology company developing small molecule drugs for cancer, using structure-based drug design against targets such as HIF2α, CDK2, KRAS, and SHP2.
BiotechHealthtechWilmington, CN
Yan Lou(Founder)inZhenhai Gao(President, CEO, and Secretary)Hong (Kelsey) Chen(Chief Financial Officer)
BoardGary Yeung(Director)Ting Jia(Director)Roderick Wong(Director)
Co-investorsEcoR1 CapitalHBM Healthcare InvestmentsHBM PartnersLAVLilly Asia VenturesRA Capital+3 more
Nura Bio develops neuroprotective medicines targeting neurological diseases by translating scientific advances in axonal degeneration and neuroimmune regulation into novel therapeutics.
BiotechDeep TechDigital HealthHealthtechMedical Devices
Co-investorsThe Column GroupSanofi Ventures
Pathalys Pharma is a biotechnology company developing and improving therapeutic treatments for patients with chronic kidney disease.
BiotechHealthtechResearch Triangle Park, US
BT Slingsby(Co-Founder & Executive Chairman)in
Co-investorsAbingworthCatalys PacificOrbiMedKB Investment
Primmune Therapeutics develops PRTX007, an orally administered, systemically active TLR7 agonist that activates interferon-associated innate immune pathways for use in cancer immunotherapy.
BiotechHealthtechCarlsbad, US
James Appleman(SVP, R&D and CSO, Cofounder)Paulo Rangel(Chief Business Officer and Cofounder)inStephen Webber(Vice President, Medicinal Chemistry, and Cofounder)inCharles McDermott(President & CEO, Director)
BoardTodd J Harris(Director)in
Co-investorsBioBritBioRock VenturesBioqube VenturesOberland CapitalPolaris Partners
BiotechFremont, US
Avanish Vellanki(Executive Officer)in
Co-investorsBiotechnology Value FundJanus Henderson Investors
RayzeBio develops radiopharmaceutical therapies for cancer treatment.
BiotechHealthtechMedical DevicesSan Diego, US
Ken Song(Executive Officer, Director)inBen Hickey(President)inAbhi Bhat, PhD(Senior Vice President, Research & Development)Deborah Charych(Executive Officer)Yi Larson(Director)
BoardAaron Royston(Director)in
Co-investorsLifeSci Venture PartnersScion Life SciencesSofinnova VenturesTCG CrossovervenBio PartnersVersant Ventures+4 more
Respira develops inhaled therapeutic products for pulmonary diseases, including a novel dry-powder inhalation device and lead product candidate RT234 for pulmonary arterial hypertension.
BiotechDigital HealthHealthtechMedical Devices
John Kollins(Chief Executive Officer)in
Co-investorsCottonwood Technology FundZentynel Frontier Investments
Septerna is a biotechnology company that uses its proprietary Native Complex Platform to discover and develop oral small molecule therapies targeting GPCRs for endocrinology, immunology and inflammation, and metabolic diseases.
AI & Machine LearningBiotechDeep TechSouth San Francisco, US
Robert Lefkowitz(Founder)Arthur Christopoulos(Founder)Patrick Sexton(Founder)Ran Xiao(Executive Officer)inElizabeth Bhatt(Executive Officer)Samira Shaikhly(Executive Officer)in
Co-investorsCatalio Capital Management, LPRA CapitalVertex Ventures HCThird Rock Ventures
Simcha is a biotechnology company developing new cancer medicines based on immune biology research.
BiotechHealthtechNew Haven, US
Aaron Ring(Executive Officer, Director)inBeatrice McQueen(Chief Operating Officer)inSanuj Ravindran(Chief Executive Officer)Jeremy Barton(Chief Medical Director)Hirdesh Uppal(Senior Vice President Translational Research and Development Sciences)Joseph Catino(Executive Officer)
Co-investorsConnecticut InnovationsPfizer Venture InvestmentsSR One Capital ManagementAxial VCBiotechnology Value FundRock Springs Capital
Biotechnology company developing products for overactive bladder and irritable bowel syndrome.
BiotechMalvern, US
Douglas Gessl(Executive Officer)inJames Walker(Executive Officer, Director)in
BoardScott Morenstein(Director)David Hirsch(Director)James Bennethum(Director)Stephen Tullman(Director)
Co-investorsFountain Healthcare PartnersLongitude Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Chinook Therapeutics U.SFl2021-001AlentarAlpheusAutobahn Labs, LLCBE BiopharmaBionic Sight, Inc.Chinook TherapeuticsCodex Health, Inc.Decibel TherapeuticsDICE TherapeuticsExcellergy TherapeuticsForma TherapeuticsGraphite Bio, Inc.IntegerBio, Inc.IVERIC BioLink Cell TherapiesMaro BioMemento MedicinesMiroBioNkarta TherapeuticsOnKure, Inc.OttimoPalladio BiosciencesRaniRespira TherapeuticsShenandoahSideraSpringWorks TherapeuticsTentarix Biotherapeutics, LPVignette Bio
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 26
19 IPOs · 7 acquisitions · showing 25aTYR PHARMANASDAQ: ATYRMineralys TherapeuticsNASDAQ: MLYSNeurogeneNASDAQ: NGNENkarta, Inc.NASDAQ: NKTXSutrobioNASDAQ: STROVtvtherapeuticsNASDAQ: VTVTAgios PharmaceuticalsNASDAQ: AGIOAlumisNASDAQ: ALMSBolt BiotherapeuticsNASDAQ: BOLTContineum TherapeuticsNASDAQ: CTNMGossamer BioNASDAQ: GOSSKalaris Therapeutics, Inc.NASDAQ: KLRSLENZ Therapeutics, Inc.NASDAQ: LENZPalvellatxNASDAQ: PVLAPrime MedicineNASDAQ: PRMEScholar Rock Holding Corp, Inc.NASDAQ: SRRKSpyglass PharmaNASDAQ: SGPUpstream BioNASDAQ: UPBAcelyrinacq. by AlumisDecibel Therapeuticsacq. by RegeneronExcellergy Therapeuticsacq. by NovartisEyebiotechacq. by MerckForma Therapeuticsacq. by Novo NordiskHilleVaxacq. by XOMA RoyaltyIntercept Pharmaceuticalsacq. by Alfasigma
Portfolio news
latest coverage across their companiesNeurogene · stocktitan.net · Sep 8, 2026
Prime Medicine · biospace.com · Sep 3, 2026
Contineum Therapeutics · stocktitan.net · Aug 25, 2026
Abcuro · finsmes.com · Aug 18, 2026
Nura Bio · finsmes.com · Jun 22, 2026
Enara Bio · scalingeurope.co.uk · Jun 2, 2026
Coultreon · coultreon.com · Apr 28, 2026
Primmune Therapeutics · globenewswire.com · Jan 26, 2026
IPO stake values · per SEC filings · 6
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| LENZ Therapeutics, Inc. | 12.4% | $17.00 | Jun 2021 | $117.8M |
| Mineralys Therapeutics | 9.2% | $16.00 | Feb 2023 | $57.3M |
| Upstream Bio | 4.0% | $17.00 | Oct 2024 | $35.1M |
| Alumis | 3.3% | $16.00 | Jun 2024 | $27.3M |
| Spyglass Pharma | 4.7% | $16.00 | Feb 2026 | $23.8M |
| Sutrobio | 4.1% | $15.00 | Sep 2018 | $13.9M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has Samsara BioCapital made?
- Samsara BioCapital has 107 tracked investments, 26 of which have exited, including 11 dated in the last 24 months.
- What stage does Samsara BioCapital invest at?
- Samsara BioCapital invests at the Seed, Series A, Series B, Series C stages.
- What sectors does Samsara BioCapital focus on?
- Samsara BioCapital focuses on AI & Machine Learning, Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Samsara BioCapital located?
- Samsara BioCapital is headquartered in Menlo Park, US.
- Does Samsara BioCapital lead rounds?
- Samsara BioCapital has led 4 of the 27 rounds where its role is on record.
- Who does Samsara BioCapital co-invest with?
- Samsara BioCapital most often shares deals with RA Capital, New Enterprise Associates (NEA), OrbiMed, among 120 tracked co-investors.
- What size deals does Samsara BioCapital back?
- Across 12 deals with disclosed amounts, Samsara BioCapital has joined rounds of $12M – $115M (median $66.9M).
Co-investors · 18
RA Capital Management is a healthcare and planetary health investment firm that founds, funds, and scales companies using scientific diligence, multi-stage capital, and hands-on operational support.
OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.
Versant Ventures operates in-house Discovery Engines staffed by multidisciplinary scientists in dedicated laboratory facilities to help launch new biotechnology companies alongside academic founders.
SR One Capital Management is a life sciences venture capital firm that takes a 'back-and-build' approach, providing entrepreneurs with human, intellectual, and financial resources. It emerged from the legacy SR One team formerly part of GSK.
Pfizer Venture Investments is a strategic venture fund that doesn't require product or technology rights as a condition of investing, giving founders independence while still aiming for future collaboration with Pfizer, and its team blends venture investing with business development and drug discovery expertise to back frontier scientific bets—such as neuroscience, in-vivo cell engineering, dark-genome target discovery, and the blockchain-based longevity accelerator VitaDAO—that many biotech investors avoid. The fund also runs an active China strategy through a locally based venture vehicle and direct investments like OTR Therapeutics, and it has become a channel for strategic deals, with portfolio companies acquired by AbbVie, Ipsen, and Gilead/Kite.
Nextech Invest is a Zurich-based investor backing emerging biotechnology companies worldwide, focused on advancing precision medicine and transformative cancer therapies.
venBio is a life sciences venture capital firm that partners with industry leaders to develop novel therapeutics and technologies addressing unmet medical needs.
Third Rock Ventures is a venture capital firm that discovers, launches, and builds life sciences and biotechnology companies developing novel medicines and therapies.
The Column Group (TCG) is a venture capital ecosystem focused on the life sciences, funding scientific innovation and building biotech companies from formation through exit.
General Catalyst is a venture capital firm operating as a partnership focused on company building and accelerating the growth of the businesses it backs.
Frazier Healthcare Partners is a healthcare-focused private equity firm that partners with profitable, growing healthcare companies to drive scale and long-term value, pairing high-conviction investment themes with experienced executives.
▶6 more co-investors
EQT Life SciencesFlagship PioneeringAdvent Life SciencesLightstone VenturesGenoa VenturesAmplitude Venture Capital
Firms observed investing alongside Samsara BioCapital, from public investor directories. Shared companies are the overlap with Samsara BioCapital's recorded portfolio.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.